Content deleted Content added
→top: update ref |
Zoingeroing (talk | contribs) →Names: Added sources, removed refs tag |
||
Line 156:
===Names===
▲''Lacosamide'' is the international nonproprietary name (INN). It was formerly known as erlosamide, harkeroside,<ref name="Beyreuther 21–42" /> SPM-927,<ref name="Beyreuther 21–42" /> and ADD-234037.<ref name="Beyreuther 21–42" />
Lacosamide is sold under the brand name Vimpat by [[UCB (company)|UCB]], and under the brand name Motpoly XR by Acute Pharmaceuticals.<ref>{{Cite web |date=2023-02-22 |title=Lacosamide |url=https://www.epilepsy.com/tools-resources/seizure-medication-list/lacosamide |access-date=2023-07-05 |website=Epilepsy Foundation |language=en}}</ref><ref>{{Cite web |title=Motpoly XR (lacosamide) – New drug approval |url=https://professionals.optumrx.com/publications/library/drugapproval_motpolyxr_2023-0508.html |access-date=2023-07-05 |website=professionals.optumrx.com |language=en}}</ref> In [[Pakistan]], it is marketed by [[G.D. Searle, LLC|G.D. Searle]] as Lacolit.<ref>{{Cite web |title=Alternate brands of LACOLIT |url=https://www.druginfosys.com//brand.aspx?code=44896 |access-date=2023-07-05 |website=www.druginfosys.com}}</ref>
== Research ==
| |||